Orphan Drugs: From Niche to Mainstream
PharmExec
JUNE 15, 2022
Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.
orphan-drugs-from-niche-to-mainstream 
52 
Evaluate’s Orphan Drug Report 2022
pharmaphorum
JUNE 20, 2022
Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within the orphan drug market and forecasts what the future of the industry holds based on data. Revising legislation.
Let's personalize your content